Table 4 Randomized clinical trials of HCC treatment with SA monotherapy
Publication | Type of study | Number of enrolled patients and controls | Type of Cancer | SA used for treatment | Response to treatment-outcome | |
|---|---|---|---|---|---|---|
| Â | Â | Patients | Controls | Â | Â | Â |
Kourumalis 1998[220] | RCT | 28* | 30# | Advanced HCC | OCT SC (500 μg/d) | ↓AFP,↑S, ↑QoL |
Yuen 2002[221] | RCT | 35* | 35° | Advanced HCC | OCT LAR (30 mg/28d) | None |
Dimitroulopoulos 2007[166] | RCT | 24* (Octreoscan +) | 30° (Octreoscan +) | Advanced HCC | OCT LAR (20 to 30 mg/28d) | ↑S, ↑QoL |
66# (Octreoscan -) | ||||||
Becker 2007[223] | RCT | 60* | 59° | Advanced HCC | OCT LAR (30 mg/28d) | None |
Barbare 2009[224] | RCT | 135* | 137° | Advanced HCC | OCT LAR (30 mg/28d) | =S, ↓QoL |